Share on StockTwits

OncoGenex Pharmaceuticals (NASDAQ:OGXI) CMO Cindy Jacobs sold 5,650 shares of the stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $3.17, for a total value of $17,910.50. Following the sale, the chief marketing officer now directly owns 43,255 shares of the company’s stock, valued at approximately $137,118. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) remained flat at $3.30 during during mid-day trading trading on Friday. The stock had a trading volume of 81,379 shares. OncoGenex Pharmaceuticals has a one year low of $2.86 and a one year high of $14.25. The stock has a 50-day moving average of $3.24 and a 200-day moving average of $6.97. The company’s market cap is $69.8 million. OncoGenex Pharmaceuticals also saw a large decline in short interest in July. As of July 31st, there was short interest totalling 305,595 shares, a decline of 45.7% from the July 15th total of 562,692 shares. Based on an average daily volume of 113,186 shares, the short-interest ratio is currently 2.7 days. Approximately 1.6% of the shares of the stock are sold short.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) last released its earnings data on Thursday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.08. Analysts expect that OncoGenex Pharmaceuticals will post $-1.75 EPS for the current fiscal year.

OncoGenex Pharmaceuticals, Inc (NASDAQ:OGXI) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.